Related Experiment Video
Updated: Jul 24, 2025
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Myopia control: short-term effect of 0.01% atropine vs. defocus incorporated multiple segment lenses-a retrospective
Sandra Guimarães1,2,3, Patrícia Barros da Silva4,5, Bárbara Oliveiros6,7
1Instituto de Investigação, Inovação e Desenvolvimento da Universidade Fernando Pessoa (FP-I3ID), Gondomar, Porto, Portugal.
Insights
DIMS spectacle lenses showed better results in slowing axial length elongation compared to 0.01% atropine eyedrops for myopia control in children. Both treatments had similar effects on spherical equivalent progression over a short follow-up period.
Area of Science:
- Ophthalmology
- Pediatric Optometry
Background:
- Myopia progression is a significant concern in pediatric populations.
- Effective myopia control strategies are crucial for preventing long-term visual impairment.
Purpose of the Study:
- To compare the efficacy of 0.01% atropine eyedrops versus DIMS (Defocus Incorporated Multiple Segments) spectacle lenses in preventing myopia progression in European children.
Main Methods:
- Retrospective study of pediatric European patients with myopia.
- Data collected from November 2021 to October 2022.
- Comparison of axial length (AL) and spherical equivalent (SE) changes at 6 months between atropine and DIMS lens groups.
Main Results:
- The DIMS lens group showed significantly lower axial length elongation (0.002 mm) compared to the atropine group (0.057 mm) (p=0.038).
- No statistically significant difference was found in spherical equivalent progression between the two groups.
- The study included 98 eyes from 50 pediatric patients.
Conclusions:
- DIMS spectacle lenses demonstrated a greater effect in reducing axial length elongation over a short-term follow-up compared to 0.01% atropine.
- Neither treatment showed a significant difference in spherical equivalent progression.
Purpose:
To compare 0.01% atropine with DIMS spectacle lenses in the prevention of myopia progression in European children.
Methods:
This was a retrospective study including data from pediatric European patients with myopia. From November 2021 to March 2022, only 0.01% atropine was prescribed because DIMS lenses were still not available in Portugal. From March to October 2022, only DIMS spectacle lenses were prescribed due to patients' parents' preference. Myopia progression endpoints were axial length (AL) and spherical equivalent (SE) differences between before and 6 months after treatment. AL and SE evolution were compared using a general linear model with repeated measures.
Results:
The study included 98 eyes from 50 patients: 47 in the atropine group and 51 in the DIMS group. There were no statistically significant differences between groups in terms of initial AL, initial SE, sex or age. The mean AL elongation at 6 months was 0.057 mm in the atropine group (SD = 0.118) and 0.002 mm (SD = 0.077) in the DIMS group. SE progression was - 0.098 (SD = 0.232) D in the atropine group and - 0.039 (SD = 0.105) D in the DIMS group. AL elongation was significantly lower in the DIMS lens group (p = 0.038, partial Eta2 = 0.045). There was no difference in SE progression between groups (p = 0.302, partial Eta2 = 0.011).
Conclusion:
Comparison between 0.01% atropine eyedrops and DIMS spectacle lenses for slowing the progression of myopia favored DIMS lenses in terms of AL elongation in a short-term follow-up. There was no difference in terms of SE between groups.
More Related Videos
Related Concept Videos
01:16Focusing of Light in the Eye
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...